CN107709338A - 吲哚胺2,3‑双加氧酶的抑制剂 - Google Patents

吲哚胺2,3‑双加氧酶的抑制剂 Download PDF

Info

Publication number
CN107709338A
CN107709338A CN201680039221.7A CN201680039221A CN107709338A CN 107709338 A CN107709338 A CN 107709338A CN 201680039221 A CN201680039221 A CN 201680039221A CN 107709338 A CN107709338 A CN 107709338A
Authority
CN
China
Prior art keywords
mmol
compound
bromo
oxadiazol
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680039221.7A
Other languages
English (en)
Chinese (zh)
Inventor
W.M.卡兹米尔斯基
M.A.德拉罗萨
V.萨马诺
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CN107709338A publication Critical patent/CN107709338A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/22—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201680039221.7A 2015-07-02 2016-06-30 吲哚胺2,3‑双加氧酶的抑制剂 Pending CN107709338A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562187937P 2015-07-02 2015-07-02
US62/187937 2015-07-02
PCT/IB2016/053947 WO2017002078A1 (en) 2015-07-02 2016-06-30 Inhibitors of indoleamine 2,3-dioxygenase

Publications (1)

Publication Number Publication Date
CN107709338A true CN107709338A (zh) 2018-02-16

Family

ID=56363880

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680039221.7A Pending CN107709338A (zh) 2015-07-02 2016-06-30 吲哚胺2,3‑双加氧酶的抑制剂

Country Status (11)

Country Link
US (1) US10239894B2 (https=)
EP (1) EP3317287B1 (https=)
JP (1) JP6654208B2 (https=)
KR (1) KR20180022988A (https=)
CN (1) CN107709338A (https=)
AU (1) AU2016285483B2 (https=)
BR (1) BR112017028456A2 (https=)
CA (1) CA2990335A1 (https=)
ES (1) ES2752455T3 (https=)
RU (1) RU2018101431A (https=)
WO (1) WO2017002078A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108530444A (zh) * 2018-06-11 2018-09-14 中国药科大学 一种新型nampt和ido双重抑制剂及其制备方法和医药用途
CN110156629A (zh) * 2019-05-30 2019-08-23 广州药本君安医药科技股份有限公司 丙卡巴肼的合成方法
WO2025119216A1 (zh) * 2023-12-04 2025-06-12 珠海联邦制药股份有限公司 硼酸类β-内酰胺酶抑制剂及其制备方法和应用

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020092528A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
US11203591B2 (en) 2018-10-31 2021-12-21 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds
EP3972695A1 (en) 2019-05-23 2022-03-30 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
EP4052705A1 (en) 2021-03-05 2022-09-07 Universität Basel Vizerektorat Forschung Compositions for the treatment of ebv associated diseases or conditions
MX2023010371A (es) 2021-03-05 2024-02-12 Univ Basel Composiciones para el tratamiento de enfermedades o condiciones asociadas al veb.

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101212967A (zh) * 2005-05-10 2008-07-02 因塞特公司 吲哚胺2,3-双加氧酶调节剂及其用法
CN102164902A (zh) * 2008-07-08 2011-08-24 因塞特公司 作为吲哚胺2,3-双加氧酶的抑制剂的1,2,5-二唑
WO2014066834A1 (en) * 2012-10-26 2014-05-01 The University Of Chicago Synergistic combination of immunologic inhibitors for the treatment of cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB427857A (en) 1934-08-02 1935-05-01 Newsum Sons & Company Ltd H A new or improved system of construction for skeleton structures, particularly vehicle body frames and door frames
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
EP1378509A4 (en) 2001-03-19 2009-03-25 Ono Pharmaceutical Co DRUGS WITH TRIAZASPIRO ç5.5] UNDECANDERIVATES AS ACTIVE SUBSTANCE
UA91560C2 (ru) 2005-08-31 2010-08-10 Селджин Корпорэйшн Соединения ряда изоиндолимидов, их композиция и применение
AU2011329485A1 (en) * 2010-11-18 2013-04-18 Glaxo Group Limited Compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101212967A (zh) * 2005-05-10 2008-07-02 因塞特公司 吲哚胺2,3-双加氧酶调节剂及其用法
CN102164902A (zh) * 2008-07-08 2011-08-24 因塞特公司 作为吲哚胺2,3-双加氧酶的抑制剂的1,2,5-二唑
WO2014066834A1 (en) * 2012-10-26 2014-05-01 The University Of Chicago Synergistic combination of immunologic inhibitors for the treatment of cancer

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108530444A (zh) * 2018-06-11 2018-09-14 中国药科大学 一种新型nampt和ido双重抑制剂及其制备方法和医药用途
CN110156629A (zh) * 2019-05-30 2019-08-23 广州药本君安医药科技股份有限公司 丙卡巴肼的合成方法
WO2025119216A1 (zh) * 2023-12-04 2025-06-12 珠海联邦制药股份有限公司 硼酸类β-内酰胺酶抑制剂及其制备方法和应用

Also Published As

Publication number Publication date
AU2016285483B2 (en) 2018-07-19
RU2018101431A (ru) 2019-08-05
WO2017002078A1 (en) 2017-01-05
BR112017028456A2 (pt) 2018-08-28
KR20180022988A (ko) 2018-03-06
ES2752455T3 (es) 2020-04-06
JP6654208B2 (ja) 2020-02-26
JP2018521056A (ja) 2018-08-02
US10239894B2 (en) 2019-03-26
EP3317287A1 (en) 2018-05-09
AU2016285483A1 (en) 2018-01-04
EP3317287B1 (en) 2019-07-31
US20180298035A1 (en) 2018-10-18
CA2990335A1 (en) 2017-01-05

Similar Documents

Publication Publication Date Title
AU2016285483B2 (en) Inhibitors of indoleamine 2,3-dioxygenase
US11274102B2 (en) Compounds useful in HIV therapy
US9029391B2 (en) Isoquinoline compounds and methods for treating HIV
US10358427B2 (en) Modulators of indoleamine 2,3-dioxygenase
EP3886987B1 (en) Compounds useful in hiv therapy
CN114245795A (zh) 作为人类免疫缺陷病毒复制抑制剂的吡啶并[2,3-d]嘧啶衍生物
TW201120016A (en) Novel oxadiazole compounds
US20170217954A1 (en) Cyano-substituted imidazo[1,2-a]pyridinecarboxamides and their use
WO2021107066A1 (ja) インテグラーゼ阻害剤及び抗ｈｉｖ薬を組み合わせることを特徴とするｈｉｖ感染症の予防及び治療用医薬
US20240051972A1 (en) Compounds Useful in HIV Therapy
US10583140B2 (en) Ingenol analogs, pharmaceutical compositions and methods of use thereof
JP2018520162A (ja) ヒト免疫不全ウイルス複製の阻害剤としてのピリジン−３−イル酢酸誘導体
KR20180054826A (ko) Hiv 성숙 억제 활성을 갖는 화합물
US20240409531A1 (en) Benzoxazinone derivatives as selective cytotoxic agents
HK40052462B (en) Compounds useful in hiv therapy
HK40052462A (en) Compounds useful in hiv therapy
JP2022543319A (ja) Ｈｉｖ治療に有用な化合物
JP2018521093A (ja) Ｈｉｖ感染を予防または治療するためのベツイン誘導体
CN108026139A (zh) 用于预防或治疗hiv感染的白桦脂醇衍生物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180216